Hypogonadism

Testosterone Therapy for Hypogonadism Not Tied to Increased CV Risk

Publish Date June 17, 2022

No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety

Morbid Obesity Ups Odds of Multiple Urologic Conditions

Publish Date May 14, 2022

Efforts to reduce obesity may cut the prevalence of these urological conditions.

FDA Approves Oral Testosterone Replacement Therapy Tlando

Publish Date April 6, 2022

The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.

Cardiovascular Events, VTE Tied to Polycythemia During Testosterone Therapy

Publish Date January 31, 2022

Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism.

Testosterone Therapy for Hypogonadism May Cut Risk for CV Events

Publish Date July 22, 2021

Risk for myocardial infarction or stroke lower with testosterone therapy among men with hypogonadism and other cardiovascular risk factors

COVID-19 Is Associated With Low Testosterone in Men

Publish Date July 10, 2021

Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.

e-ECE: Testosterone Therapy Mitigates NAFLD in Obese Men With FH, T2D

Publish Date June 16, 2021

Testosterone undecanoate therapy reduces NAFLD grade in obese men with functional hypogonadism and type 2 diabetes

Severe COVID-19 Associated With Low Testosterone in Men

Publish Date May 27, 2021

It is unclear whether low testosterone is a marker or a mediator of severe and impending severe COVID-19 illness.

Inflammatory Diet May Contribute to Testosterone Deficiency in Men

Publish Date April 29, 2021

Each 1 unit increment in Dietary Inflammatory Index was associated with a 4.0% increase in the odds of testosterone deficiency.

Kyzatrex Under Review for Primary and Secondary Male Hypogonadism

Publish Date March 16, 2021

Kyzatrex is an investigational, oral testosterone undecanoate softgel that utilizes lymphatic absorption and phytosterols to increase bioavailability and provide a favorable pharmacokinetic profile.